All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lactobacillus Reuteri
Therapeutic Area: Gastroenterology Product Name: IBP-9414
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2021
Details:
IBT is currently developing IBP-9414 to prevent necrotizing enterocolitis, and to improve feeding tolerance in premature infants. IBP-9414 contains Lactobacillus reuteri as an active ingredient, which is a human bacterial strain found naturally in breast milk.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cobitolimod
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Vinnova
Deal Size: $0.1 million Upfront Cash: Undisclosed
Deal Type: Funding March 31, 2020
Details:
The grant will be used for a preclinical project to evaluate selected compounds from InDex's DIMS platform in inflammatory disease models outside the field of inflammatory bowel disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Linaprazan
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Fourth Swedish National Pension Fund
Deal Size: $25.6 million Upfront Cash: Undisclosed
Deal Type: Financing March 04, 2020
Details:
The proceeds from the financing round will be used to perform a phase 2 clinical trial, which is expected to start in the second half of 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cobitolimod
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2020
Details:
The paper shows that the Toll-like receptor 9 (TLR9) agonist cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cobitolimod
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2020
Details:
The Phase IIb dose optimisation study CONDUCT, is evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
